Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

cts an estimated 3,500 to 5,000 Canadians.  Approximately one-third of IPF patients in Canada are covered by private insurance and up to six months are needed to secure coverage for new medicines from the major private insurance companies in Canada.  Public (provincial) drug reimbursement plans cover approximately two-thirds of IPF patients in Canada and, on average, about 18 months are needed to secure reimbursement from all 10 provincial governments.
  • On January 9, 2013, enrollment was completed in the confirmatory Phase 3 pirfenidone study, ASCEND, designed to support marketing approval in the United States.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration, followed by an approximate five-week safety follow up, with a primary endpoint of change in Forced Vital Capacity (FVC) between baseline and Week 52.  The trial enrolled 555 IPF patients with mild-to-moderate impairment in lung function.  InterMune expects that top-line results from the study will be available in the second quarter of 2014.
  • On February 19, 2013, InterMune reported that the company and Shionogi & Co., Ltd had reached an agreement regarding the material terms of a settlement of the complaint filed by Shionogi against InterMune.  Effective January 1, 2013, InterMune agrees to pay Shionogi a royalty of 4.25% on net sales of Esbriet in the European Union through the remaining period of Orphan Drug exclusivity ending in February 2021.  Shionogi waives any claim against InterMune to royalties on Esbriet sales in Canada or in the United States.
  • On March 4, 2013, InterMune announced that the Pricing Commission (CPR) of the Italian Drug Agency (AIFA) had agreed to pricing and reimbursement conditions for Esbriet.  InterMune anticipates that the launch of Esbriet in Italy will begin following formal approval of the agreement by the Agency Board and publication in the Official Gazette, which is expected in
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    8. InterMune To Release First Quarter Financial Results On April 24
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... , March 4, 2015 Vegalab announced ... in August of last year. As part of the ... Bon Koo continuing his role as CEO for ... of Vegalab S.A., will work alongside Koo and oversee ... - http://photos.prnewswire.com/prnh/20150303/179218 Koo founded ...
    (Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
    (Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... the "Gene Therapy Market, 2015 - 2025" ... Therapy Market, 2015-2025" report provides an extensive study on ... research has been carried out in this field for ... therapies (four available in Asian markets; one approved in ...
    (Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
    Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
    ... announced that the first patient has received an initial ... first oncology product, MM-121, a,fully human monoclonal antibody and ... receptor., ErbB3 is a receptor in the ErbB ... signaling. With the initiation of the Phase 1 trial, ...
    ... Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- China,Bionanometer Industries Corporation ... the bionanometer industry, has promoted a new ... thorough period of,scientific verification, research and experiments. ... over six months in the northeast region ...
    ... at The University of Texas at San Antonio (UTSA) South ... Texas Health Science Center at San Antonio (UTHSCSA) have identified ... the early infectious process against Francisella tularensis, a ... tularemia. The findings will be released this week in a ...
    Cached Biology Technology:Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist 3China Bionanometer Industries Corporation Promotes New Product 'Beauty Look' in China 2UTSA/UTHSCSA publish results on bio-threat agent 2
    (Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
    (Date:3/2/2015)... , March 2, 2015   Neurotechnology , a ... introduced the SentiGaze Software Development Kit (SDK). ... applications that use off-the-shelf webcams to track eye movements ... at a monitor. Heatmaps can be used for applications ... of online advertising. The SDK can also be used ...
    (Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
    Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
    ... animals a unique fish that lives on land and can ... and complex social life, a new study has found., The odd ... been detailed for the first time in research findings that throw ... land., The Pacific leaping blenny is a marine fish yet is ...
    ... could protect crucial habitat for the vast majority of ... according to researchers at Stanford University and the National ... the Aug. 16 edition of the Proceedings of ... 129 species of marine mammals on Earth, including seals, ...
    ... August 29, 2011 Collaborating researchers at Stanford ... compounds that show promise as potential therapeutics for a ... together of a protein known as transthyretin (TTR). ... TTR protein, work by holding the protein together in ...
    Cached Biology News:Landlubber fish leap for love when tide is right 2Preserving 4 percent of the ocean could protect most marine mammal species, study finds 2Preserving 4 percent of the ocean could protect most marine mammal species, study finds 3Scientists find new drug candidates for set of protein-folding diseases 2Scientists find new drug candidates for set of protein-folding diseases 3
    ... a high-throuput screening of a biological systems ... induced changes in the expression levels of ... detected, studied, classified and compared to each ... at a glance. Automatized scanning of the ...
    ... agitation and temperature control for microbiology and ... independently and is suitable for DASGIP bioreactors ... volume. Its temperature ranges from approximately 10 ... is equipped with an individual electrical heating ...
    ... stain is a sensitive nucleic acid gel ... RNA and low background in gels, making it ... gels using laser scanners or standard UV transilluminators. ... unit size (S-7564) and a special packaging (S-7586) ...
    Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
    Biology Products: